COMPANY

Sapience Therapeutics

HQ: Tarrytown, NY source · sapiencetherapeutics.com ↗ · Mid-Atlantic

Keywords: oncology cancer Breast Cancer sars-cov-2 infection Familial Adenomatous Polyposis Colon Cancer Metastatic Colon Cancer Glioblastoma Melanoma Stage IV Prostate Cancer Glioblastoma Multiforme GBM Brain Cancer Metastatic Breast Cancer Metastatic Melanoma Metastatic Prostate Cancer Melanoma Recurrent Prostate Cancer Metastatic Recurrent Glioblastoma Newly Diagnosed Glioblastoma ST316 ST101

Location: Tarrytown, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)8NIH grants

Timeline

Jan 4, 2027 Trial start Phase 1: A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). source ↗
Jun 5, 2023 Trial start 1: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors source ↗
Jul 1, 2020 Trial start 1: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

2026-12 (ESTIMATED) · 1 · A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors · NCT04478279
Dec 31, 2026 (ESTIMATED) · 1 · A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors · NCT05848739
Dec 31, 2028 (ESTIMATED) · Phase 1 · A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). · NCT07729371

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07729371	A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).	Phase 1	Not yet recruiting	Jan 4, 2027	Dec 31, 2028 (estimated)
NCT05848739	A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors	1	Active, not recruiting	Jun 5, 2023	Dec 31, 2026 (estimated)
NCT04478279	A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors	1	Active, not recruiting	Jul 1, 2020	2026-12 (estimated)

NIH awards 8

Annual award amounts. Total $4.7M.

Apr 26, 2024 NIH award 5R44CA265503-03 FY2024: $632,111 awarded for that fiscal year; activity R44 (SBIR); PI ROTOLO, JIM; recipient as written: SAPIENCE THERAPEUTICS, INC., Tarrytown, NY. Development of a cell-penetrating beta-c source ↗
Jul 20, 2023 NIH award 5R44CA250786-03 FY2023: $803,479 awarded for that fiscal year; activity R44 (SBIR); PI ROTOLO, JIM; recipient as written: SAPIENCE THERAPEUTICS, INC., Tarrytown, NY. Efficacy and PK/PD of a C/EBP beta antag source ↗
May 1, 2023 NIH award 2R44CA265503-02A1 FY2023: $1,362,268 awarded for that fiscal year; activity R44 (SBIR); PI ROTOLO, JIM; recipient as written: SAPIENCE THERAPEUTICS, INC., Tarrytown, NY. Development of a cell-penetrating be source ↗
Aug 10, 2022 NIH award 2R44CA250786-02 FY2022: $631,607 awarded for that fiscal year; activity R44 (SBIR); PI ROTOLO, JIM; recipient as written: SAPIENCE THERAPEUTICS, INC., Tarrytown, NY. Efficacy and PK/PD of a C/EBP beta antag source ↗
Apr 22, 2022 NIH award 5R43AI157521-02 FY2022: $288,178 awarded for that fiscal year; activity R43 (SBIR); PI ROTOLO, JIM; recipient as written: SAPIENCE THERAPEUTICS, INC., Tarrytown, NY. Inhibition of SARS-CoV-2 infection with source ↗
Sep 2, 2021 NIH award 1R43CA265503-01 FY2021: $409,295 awarded for that fiscal year; activity R43 (SBIR); PI ROTOLO, JIM; recipient as written: SAPIENCE THERAPEUTICS, INC., Tarrytown, NY. Development of a cell-penetrating beta-c source ↗
May 4, 2021 NIH award 1R43AI157521-01A1 FY2021: $299,860 awarded for that fiscal year; activity R43 (SBIR); PI ROTOLO, JIM; recipient as written: SAPIENCE THERAPEUTICS, INC., Tarrytown, NY. Inhibition of SARS-CoV-2 infection wit source ↗
Aug 5, 2020 NIH award 1R43CA250786-01A1 FY2020: $255,240 awarded for that fiscal year; activity R43 (SBIR); PI ROTOLO, JIM; recipient as written: SAPIENCE THERAPEUTICS, INC., Tarrytown, NY. Efficacy and PK/PD of a C/EBP beta ant source ↗